HMA - Heads of Medicines Agencies
  • RSS
  • Sitemap
  • Login (HMA-DMS)
  • Contact
  • About HMA
  • Human Medicines
  • Veterinary Medicines
  • You are here:
  • Home
  • >Human Medicines
  • >CMDh
  • >Procedural Guidance
  • >Art 61.3 Procedure
  • CMDh
    • About CMDh
    • Statistics
    • Agendas and Minutes
    • Press Releases
    • COVID-19
    • BREXIT
    • Procedural Guidance
      • General Info
      • Application for MA
      • eSubmissions
      • Generics
      • Applicant´s Responses
      • Renewal
      • Consultation with target patient groups
      • Variation
      • USR
      • Art 61.3 Procedure
      • Post Referral Phase
    • CMDh-Referrals
    • Product Information
    • Advice from CMDh
    • Templates
    • CMD Working Parties / Working Groups
    • Paediatric Regulation
    • Pharmacovigilance
    • Falsified Medicines
    • Questions & Answers
    • Contact Points
    • Recently Published history
  • MRI Product Index
  • Pharmacovigilance
  • Availability of Medicines
  • Publications and reports
  • National Contacts

 

Art. 61.3 Procedure

In order to view some of the documents on this website you need Acrobat Reader
(click here to download)

  • CMDh Standard Operating Procedure for Article 61(3) changes to patient information and the notification for product information amendment under Article 61(3) (not accompanying a variation change) (October 2011) [Track version]
  • Flowchart for the Article 61(3) procedure (July 2007)
  • Notification Form (June 2020) [PDF]

The United Kingdom (UK) withdrew from the European Union (EU) on 31 January 2020 and is no longer an EU Member State. HMA and CMDh/v are in the process of making appropriate changes to this website. If the site still contains content that does not yet reflect the withdrawal of the UK from the EU, this is unintentional and will be addressed. In case you notice information that should be updated, please report this website link using the contact form.

  • Useful Links
  • Privacy Policy
  • Credits & Disclaimer
  • Contact
© Heads of Medicines Agencies - https://www.hma.eu/human-medicines/cmdh/procedural-guidance/art-613-procedure.html